生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1161 生物科技

交易中 05-12 14:05:28

5,661.655

-45.161

-0.79%

最高5,775.761	最低5,643.607	成交量1.07亿
今开5,710.234	昨收5,706.816	日振幅2.32%
总市值0.00	流通市值0.00	总股本0.00
成交额34.77亿	换手率--	流通股本0.00
市净率6.025751	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1161","market":"HK","secType":"PLATE","nameCN":"生物科技","latestPrice":5661.655,"timestamp":1778565928242,"preClose":5706.816,"halted":0,"volume":107208876,"delay":0,"changeRate":-0.007914,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-45.161133,"latestTime":"05-12 14:05:28","open":5710.2344,"high":5775.761,"low":5643.6074,"amount":3476897980,"amplitude":0.023157,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1778573400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1778549400000,1778558400000],[1778562000000,1778572800000]],"pbRate":6.025751,"peRate":-595.168608,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1161","defaultTab":"news","newsList":[{"id":"2634268476","title":"一品红：公司在研的创新药氘泊替诺雷（AR882）是一种高效选择性尿酸转运蛋白（URAT1）抑制剂，用于降低血尿酸治疗痛风及溶解痛风石","url":"https://stock-news.laohu8.com/highlight/detail?id=2634268476","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634268476?lang=zh_cn&edition=full","pubTime":"2026-05-12 11:33","pubTimestamp":1778556808,"startTime":"0","endTime":"0","summary":"证券之星消息，一品红(300723)05月11日在投资者关系平台上答复投资者关心的问题。投资者提问：5月15日,ASCO会摘录贵公司疼风药第三期临床结果吗一品红回复：尊敬的投资者您好，感谢您对公司的关注。ASCO是临床肿瘤学领域的学术会议。公司在研的创新药氘泊替诺雷（AR882）是一种高效选择性尿酸转运蛋白（URAT1）抑制剂，用于降低血尿酸治疗痛风及溶解痛风石。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200016638.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","159992","06978","BK1161","300723","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634250452","title":"港股异动 | 再鼎医药(09688)早盘涨超5% zoci获FDA快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2634250452","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634250452?lang=zh_cn&edition=full","pubTime":"2026-05-12 10:55","pubTimestamp":1778554548,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药早盘涨超5%，截至发稿，涨2.38%，报15.49港元，成交额7370.89万港元。消息面上，5月11日，据再鼎医药官微消息，公司宣布，美国食品药品监督管理局已授予具有同类首创潜力的靶向Delta样配体3的抗体药物偶联物zocilurtatug pelitecan快速通道资格认定，用于治疗在接受一线标准治疗后出现疾病进展的epNECs。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 再鼎医药(09688)早盘涨超5% zoci获FDA快速通道资格认定","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4526","LU2488822045.USD","BK1574","BK4585","BK4548","09688","BK4139","ZLAB","BK1588","BK4531","BK1161","BK1119"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634925434","title":"宝发控股(08532)股东将股票由华泰香港转入奕丰证券(香港) 转仓市值31.2万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634925434","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634925434?lang=zh_cn&edition=full","pubTime":"2026-05-12 08:31","pubTimestamp":1778545905,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，5月11日，宝发控股(08532)股东将股票由华泰香港转入奕丰证券(香港)，转仓市值31.2万港元，占比5.41%。宝发控股公布，公司已于2026年3月31日接获高等法院就公司所提交的同意传票颁发的法院命令。高等法院颁令，除其他事项外，撤回呈请，并取消原订于 2026年4月8日就呈请进行的聆讯。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["161027","BK1158","BK1148","08532","08592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634829282","title":"九源基因(02566)更名为“杭州九源基因生物医药股份有限公司”","url":"https://stock-news.laohu8.com/highlight/detail?id=2634829282","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634829282?lang=zh_cn&edition=full","pubTime":"2026-05-11 21:19","pubTimestamp":1778505581,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九源基因 发布公告，公司已于2025年4月17日取得香港公司注册处处长签发的注册非香港公司变更名称注册证明书，确认根据公司条例第16部在香港注册的公司英文名称已由“Hangzhou Jiuyuan Gene Engineering Co., Ltd.”更改为“Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.”，而中文名称已由“杭州九源基因工程股份有限公司”更改为“杭州九源基因生物医药股份有限公司”。更改公司名称后，公司的股份代号、中文股票简称及英文股票简称保持不变。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440388.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02566","XBI","BK1161","BK4585","399441","BK4581","BK4588","161726"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634257282","title":"儿童用药新政发布：商保入局，落地仍需“闯关”","url":"https://stock-news.laohu8.com/highlight/detail?id=2634257282","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634257282?lang=zh_cn&edition=full","pubTime":"2026-05-11 21:16","pubTimestamp":1778505360,"startTime":"0","endTime":"0","summary":"　　近日，国家卫生健康委、工业和信息化部等八部门发布的《关于改革完善儿童用药供应保障机制的实施意见》提出，支持商业健康保险开发儿童保险保障产品，鼓励将创新药、罕见病用药纳入保障范围。　　新政明确鼓励“商业健康保险将儿童创新药、罕见病用药纳入保障范围”，但有多位业内专家直言：面向成人的商保创新药目录当前处于“雷声大雨点小”的局面。而儿童用药的商保支付之路，挑战更大。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-05-11/doc-inhxptre2179182.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-05-11/doc-inhxptre2179182.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","06978","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634285739","title":"再鼎医药(ZLAB)自研药物Zoci获美国FDA授予快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2634285739","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634285739?lang=zh_cn&edition=full","pubTime":"2026-05-11 19:36","pubTimestamp":1778499399,"startTime":"0","endTime":"0","summary":"据悉，epNECs为侵袭性强、预后差的恶性肿瘤，全球约10万人患病，无获批靶向疗法与标准治疗方案，存在巨大未满足医疗需求。此前2025年5月，Zoci已获FDA快速通道资格，用于广泛期小细胞肺癌治疗。此外，2026年AACR年会公布的Ib/II期注册研究显示，Zoci用于多线治疗失败的epNEC患者，客观缓解率达38.2%，且安全性可控，仅中性粒细胞减少为唯一≥3级且多例出现的治疗相关不良反应。目前Zoci的epNEC临床项目正推进注册，已与药监部门沟通注册计划。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/ZmFlOWFhNTNlYzgzMTc4NTEyNzIzMzYzNzY2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZmFlOWFhNTNlYzgzMTc4NTEyNzIzMzYzNzY2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300251","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","ZLAB","BK1161","BK4548","BK1574","LABU","BK4531","BK1588","BK4526","BK4139","09688","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634285813","title":"翰思艾泰-B(03378)5月11日斥资72.5万港元回购2.26万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634285813","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634285813?lang=zh_cn&edition=full","pubTime":"2026-05-11 19:27","pubTimestamp":1778498837,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B(03378)发布公告，于2026年5月11日斥资72.5万港元回购2.26万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440330.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1173","BK1535","03378"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175506875","title":"再鼎医药DLL3靶向ADC药物Zoci获美国FDA快速通道资格，用于治疗肺外神经内分泌癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1175506875","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175506875?lang=zh_cn&edition=full","pubTime":"2026-05-11 19:04","pubTimestamp":1778497466,"startTime":"0","endTime":"0","summary":"再鼎医药旗下靶向DLL3的抗体偶联药物（ADC）Zocilurtatug Pelitecan（简称Zoci）已获得美国食品药品监督管理局（FDA）授予的快速通道资格，用于治疗肺外神经内分泌癌（Ep-NECs）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","BK1161","LU2488822045.USD","BK1574","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634400431","title":"和铂医药-B(02142)5月11日斥资214.41万港元回购16.4万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634400431","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634400431?lang=zh_cn&edition=full","pubTime":"2026-05-11 18:37","pubTimestamp":1778495876,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B(02142)发布公告，于2026年5月11日斥资214.41万港元回购16.4万股;根据于2020年11月23日采纳及获本公司股东批准的首次公开发售后股份奖励计划而发行8.7万股普通股以满足股份奖励。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1574","02142","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634288805","title":"加科思-B(01167)5月11日耗资约46.68万港元回购7.56万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634288805","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634288805?lang=zh_cn&edition=full","pubTime":"2026-05-11 18:26","pubTimestamp":1778495213,"startTime":"0","endTime":"0","summary":"加科思-B(01167)公布，2026年5月11日耗资约46.68万港元回购7.56万股股份。","market":"us","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_17.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_17.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440279.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK1161","01167"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634402283","title":"昊海生物科技(06826)5月11日斥资99.73万港元回购4.37万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634402283","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634402283?lang=zh_cn&edition=full","pubTime":"2026-05-11 17:56","pubTimestamp":1778493365,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)发布公告，于2026年5月11日，该公司斥资99.73万港元回购4.37万股股份，每股回购价22.72-22.86港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440259.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1593","06826"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634240264","title":"瑞博生物-B(06938)：核心产品VORTOSIRAN完成针对静脉血栓栓塞适应症的2b期临床试验申请递交","url":"https://stock-news.laohu8.com/highlight/detail?id=2634240264","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634240264?lang=zh_cn&edition=full","pubTime":"2026-05-11 17:42","pubTimestamp":1778492557,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B 发布公告，本公司核心产品vortosiran 已成功向欧洲药品管理局递交针对静脉血栓栓塞症防治的 2b期临床试验申请。本研究为本公司涵盖多个已规划的针对多种血栓栓塞性心血管适应症的2b期研究的一部分。Vortosiran是全球进展最快的靶向FXI的小核酸药物，及截至本公告日期，该产品已完成针对冠状动脉疾病的欧洲2a期临床试验，且其针对心房颤动的 2b期CTA已于2026年4月向EMA递交。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440240.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634019184","title":"金凯生科：公司核心业务聚焦于含氟医药中间体等小分子CDMO领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2634019184","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634019184?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:57","pubTimestamp":1778489827,"startTime":"0","endTime":"0","summary":"证券之星消息，金凯生科05月11日在投资者关系平台上答复投资者关心的问题。公司核心业务聚焦于含氟医药中间体等小分子CDMO领域，具体业务情况请以公司公开披露的信息为准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100022696.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1574","BK1161","BK1515","159938","09939","301509"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634140182","title":"康希诺生物(06185)：青少年及成人用Td5cp的NDA获国家药监局药品审评中心纳入优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=2634140182","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634140182?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:48","pubTimestamp":1778489303,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康希诺生物 发布公告，公司为其吸附无细胞百(五组分)白破联合疫苗的新药上市申请获得中国国家药品监督管理局药品审评中心纳入优先审评。根据国家优先审评审批的规定，国家药监局药品审评中心对纳入优先审评审批的NDA，将优先配置资源进行审评。青少年及成人用Td5cp适用于6岁及以上人群，为青少年及成人的百白破加强疫苗。公司正在准备青少年及成人用Td5cp的NDA递交工作","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康希诺生物(06185)：青少年及成人用Td5cp的NDA获国家药监局药品审评中心纳入优先审评","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1574","06185","BK1161","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634409612","title":"5月11日百济神州涨5.89%，万家行业优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634409612","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634409612?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:30","pubTimestamp":1778488246,"startTime":"0","endTime":"0","summary":"证券之星消息，5月11日百济神州涨5.89%，收盘报262.08元，换手率5.41%，成交量6.23万手，成交额15.82亿元。重仓百济神州的前十大公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家；过去90天内机构目标均价为330.49。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共107家，其中持有数量最多的公募基金为万家基金的万家行业优选LOF。万家行业优选LOF目前规模为58.28亿元，最新净值1.5479，较上一交易日下跌1.13%，近一年上涨31.77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100021927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1500","LU1770034418.SGD","06160","BK1583","LU0588546209.SGD","LU1719994722.HKD","BK1161","LU0307460666.USD","LU1251922891.USD","LU1303224171.USD","LU2328871848.SGD","688235","160916","LU1969619763.USD","BK0239","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634409827","title":"5月11日迈威生物涨5.80%，易方达医药生物股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634409827","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634409827?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:28","pubTimestamp":1778488118,"startTime":"0","endTime":"0","summary":"证券之星消息，5月11日迈威生物涨5.80%，收盘报37.2元，换手率6.99%，成交量14.28万手，成交额5.18亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共18家，其中持有数量最多的公募基金为易方达基金的易方达医药生物股票A。易方达医药生物股票A目前规模为19.96亿元，最新净值0.7862，较上一交易日下跌2.29%，近一年上涨13.89%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100021865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1161","02493","163118","688062","000808.SH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634409396","title":"5月11日药康生物涨6.45%，天弘医药创新A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634409396","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634409396?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:28","pubTimestamp":1778488113,"startTime":"0","endTime":"0","summary":"证券之星消息，5月11日药康生物涨6.45%创60日新高，收盘报21.8元，换手率2.05%，成交量8.41万手，成交额1.78亿元。重仓药康生物的公募基金请见下表：该股最近90天内共有4家机构给出评级，买入评级4家；过去90天内机构目标均价为25.81。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为天弘基金的天弘医药创新A。天弘医药创新A目前规模为5.71亿元，最新净值1.0214，较上一交易日下跌1.84%，近一年上涨28.72%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100021862.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1515","BK0216","BK1574","159938","688046","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634405166","title":"今日南新制药（688189）涨停分析：创新药进展、财务优化与控股股东支持驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2634405166","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634405166?lang=zh_cn&edition=full","pubTime":"2026-05-11 15:40","pubTimestamp":1778485203,"startTime":"0","endTime":"0","summary":"证券之星消息，南新制药5月11日涨停收盘，收盘价10.55元。该股于13点9分涨停，未打开涨停，截止收盘封单资金为4415.7万元，占其流通市值1.53%。5月11日的资金流向数据方面，主力资金净流入6460.46万元，占总成交额19.05%，游资资金净流出3079.1万元，占总成交额9.08%，散户资金净流出3381.37万元，占总成交额9.97%。近5日资金流向一览见下表：该股为流感，创新药，医药概念热股，当日流感概念上涨1.95%，创新药概念上涨1.85%，医药概念上涨1.58%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100015781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1161","688189","BK1574","BK0239","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634408151","title":"兴业证券：2025年医药板块企稳回升 2026Q1延续增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2634408151","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634408151?lang=zh_cn&edition=full","pubTime":"2026-05-11 14:42","pubTimestamp":1778481763,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，兴业证券发布研报称，“创新+国际化”仍将是2026年医药生物板块核心主线。兴业证券主要观点如下：2025年板块企稳回升，2026Q1延续增长医药板块所有上市公司2025年营业收入同比增加1.05%，归属上市公司股东的净利润同比增加7.92%，扣非归母净利润同比减少0.37%。2026年一季度年营业收入同比增加2.25%，归属上市公司股东的净利润同比增长5.49%，扣非归母净利润同比增长9.65%。2025年医药板块收入利润已实现企稳回升，2026Q1延续增长态势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0188","BK1574","159938","BK1161","BK0183","BK0276","BK1515","09939","601377","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634408851","title":"港股异动 | 来凯医药-B(02105)午后涨超10% 齐鲁制药推进LAE002上市申请 公司有望获首付款及里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=2634408851","media":"智通财经","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634408851?lang=zh_cn&edition=full","pubTime":"2026-05-11 14:32","pubTimestamp":1778481147,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，来凯医药-B午后涨超10%，截至发稿，涨9.63%，报14.8港元，成交额6089.13万港元。4月30日，齐鲁制药官方宣布，由其独家引进中国区域研发与商业化权益的创新靶向药afuresertib临床研究达到主要终点，齐鲁制药独家引进推进国内上市申请。作为回报，若LAE002在中国获批首个适应症，来凯医药有权获得5.3亿元不可退还的首付款与总计最高20.45亿元的里程碑款项。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02105","01477","BK4585","IPOS","BK1191","VXUS","BK1161","BK1574","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0119},{"period":"1month","weight":0.0198},{"period":"3month","weight":-0.0286},{"period":"6month","weight":-0.0192},{"period":"1year","weight":0.1548},{"period":"ytd","weight":0.0303}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1161","nameEN":"BK1161"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK1161,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}